BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, January 30, 2026
Home » Authors » Tamra Sami

Tamra Sami

Articles

ARTICLES

Australia proposes unique device identification system

Jan. 11, 2019
By Tamra Sami

Qiagen licenses Ellume's TB digital diagnostic, invests $15M

Jan. 10, 2019
By Tamra Sami

Australian researchers harness AI to sequence human genome, diagnose PTSD, breast cancer

Jan. 2, 2019
By Tamra Sami
BRISBANE, Australia – Australian researchers are using artificial intelligence (AI) to diagnose medical conditions ranging from breast cancer to post-traumatic stress disorder (PTSD) more quickly than ever before.
Read More

Australian researchers harness AI to sequence human genome, diagnose PTSD, breast cancer

Dec. 28, 2018
By Tamra Sami
BRISBANE, Australia – Australian researchers are using artificial intelligence (AI) to diagnose medical conditions ranging from breast cancer to post-traumatic stress disorder (PTSD) more quickly than ever before.
Read More

Starpharma out-licenses Vivagel BV to ITF Pharma for U.S. market for $101M

Dec. 26, 2018
By Tamra Sami
PERTH, Australia – In yet another regional carve-out deal for Starpharma Holdings Ltd., the company has out-licensed rights to its Vivagel BV for bacterial vaginosis (BV) to ITF Pharma for the U.S. market for roughly $101 million.
Read More

Investment in Australian life sciences on the rise but at a conservative clip

Dec. 26, 2018
By Tamra Sami
PERTH, Australia – More money will be deployed in Australia's life sciences sector in the next four or five years than there has ever been, according to Australia's biggest life sciences investor. Brandon Capital Partners manages four life sciences funds with A$531 million (US$374.1 million) under management. Although it's the biggest venture fund in Australia, it's fairly small compared to some of its U.S. peers.
Read More

Investment in Australian life sciences on the rise but at a conservative clip

Dec. 24, 2018
By Tamra Sami

Investment in Australian life sciences on the rise but at a conservative clip

Dec. 24, 2018
By Tamra Sami
PERTH, Australia – More money will be deployed in Australia's life sciences sector in the next four or five years than there has ever been, according to Australia's biggest life sciences investor.
Read More

Australia's TGA unveils guidance on software as a medical device

Dec. 21, 2018
By Tamra Sami

Starpharma out-licenses Vivagel BV to ITF Pharma for U.S. market for $101M

Dec. 21, 2018
By Tamra Sami
PERTH, Australia – In yet another regional carve-out deal for Starpharma Holdings Ltd., the company has out-licensed rights to its Vivagel BV for bacterial vaginosis (BV) to ITF Pharma for the U.S. market for roughly $101 million.
Read More
View All Articles by Tamra Sami

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 30, 2025.
  • Today's news in brief

    Briefs
    BioWorld MedTech briefs for Jan. 30, 2026.
  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Centessa’s CNT-9982 shows promise for MDD

    BioWorld Science
    Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
  • Red and blue bispecific antibodies

    First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

    BioWorld Science
    Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing